Last reviewed · How we verify
BTL-TML-COVID
BTL-TML-COVID is a vaccine that stimulates an immune response against SARS-CoV-2.
BTL-TML-COVID is a vaccine that stimulates an immune response against SARS-CoV-2. Used for Prevention of COVID-19 disease.
At a glance
| Generic name | BTL-TML-COVID |
|---|---|
| Sponsor | Beech Tree Labs, Inc. |
| Drug class | vaccine |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
The vaccine works by introducing a piece of genetic material from the SARS-CoV-2 virus to the body, which triggers an immune response and helps the body produce antibodies to fight the virus.
Approved indications
- Prevention of COVID-19 disease
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BTL-TML-COVID CI brief — competitive landscape report
- BTL-TML-COVID updates RSS · CI watch RSS
- Beech Tree Labs, Inc. portfolio CI